Description

Zevra Therapeutics In M&A Spotlight As Collegium Walks Away—What’s Next?

Zevra Therapeutics recently reported its second quarter 2025 financial results, showcasing noteworthy developments and challenges. The company recorded net revenue of $25.9 million, driven predominantly by their flagship product, MIPLYFFA, which contributed $21.5 million. This performance indicates a 26% revenue growth from the previous quarter, reflecting strong demand within its launch phase in the U.S. market, particularly among patients diagnosed with Niemann-Pick Disease Type C (NPC).

Our Report Structure:

⦁ Company Overview
⦁ Investment Thesis
⦁ Key Drivers
⦁ Historical Quarterly Statement Analysis – Income Statement & Cash Flows
⦁ Historical Quarterly Balance Sheet Analysis
⦁ Historical Annual Financial Statement Analysis
⦁ Analysis Of Key Financial Ratios
⦁ Financial Forecasts For 3 Years
⦁ Forecasting The Capital Structure & Net Debt
⦁ Discounted Cash Flow Valuation
⦁ Trading Multiples
⦁ Key Risks
⦁ Disclosures

Want unlimited access to our reports? Purchase our $99 annual subscription!